Lazard Asset Management
JANX icon

Lazard Asset Management’s Janux Therapeutics JANX Stock Holding History

Lazard Asset Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-97,473
Closed -$2.38M – 1961
2025
Q3 		$2.38M Sell
97,473
-2,385
-2% -$58.1K ﹤0.01% 803
2025
Q2 		$2.31M Buy
99,858
+39,278
+65% +$1.03M ﹤0.01% 969
2025
Q1 		$1.64M Sell
60,580
-21,425
-26% -$808K ﹤0.01% 1034
2024
Q4 		$4.39M Buy
+82,005
New +$4.34M 0.01% 668
2024
Q1 		– Sell
-1,734
Closed -$18K – 2216
2023
Q4 		$18K Buy
1,734
+67
+4% +$579 ﹤0.01% 2063
2023
Q3 		$16K Buy
+1,667
New +$19.2K ﹤0.01% 2122

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Lazard Asset Management's JANX Position: Q4 2025 in Review

Lazard Asset Management sold out of Janux Therapeutics (JANX) in Q4 2025, closing a stake of 97,473 shares — an estimated $2.38M sold.

Lazard Asset Management first reported a position in JANX in Q3 2023 and held it in 6 quarters. The position peaked at $4.39M in Q4 2024. 176 funds tracked by Wall St. Rank hold JANX as of Q4 2025.

  • Lazard Asset Management reported no remaining Janux Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Lazard Asset Management sold 97,473 Janux Therapeutics shares in Q4 2025, an estimated $2.38M.
  • Lazard Asset Management first reported a position in Janux Therapeutics in Q3 2023 and held it in 6 quarters.
  • Lazard Asset Management's Janux Therapeutics position peaked at $4.39M in Q4 2024.
  • 176 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2025.

Based on Lazard Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.